The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found. Among 379 participants in the efficacy ...

In 2023, esketamine showed superiority to quetiapine when it exhibited a 54% increased likelihood of patients reaching remission for treatment-resistant depression (TRD) at 8 weeks. 2 TRD affects ...

Spravato (esketamine) is a prescription nasal spray that treats depression in adults. Learn about dosage, side effects, and more.

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by an inadequate response to two or more oral antidepressants (OADs).

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

They included 55,480 participants with TRD, half of whom were treated with esketamine plus an SNRI (58.6% women; mean age, 45.9 years) and the other half with esketamine plus an SSRI (57.7% women ...

After screening and randomization, 95 patients received 84 mg esketamine, 86 patients received 56 mg esketamine, and 197 received placebo. About 61% were female, 86.8% were white, and 65.6% were ...